We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hologic (HOLX) Advances But Underperforms Market: Key Facts
Read MoreHide Full Article
Hologic (HOLX - Free Report) closed the latest trading day at $61.89, indicating a +0.68% change from the previous session's end. The stock's change was less than the S&P 500's daily gain of 1.77%. Meanwhile, the Dow gained 1.42%, and the Nasdaq, a tech-heavy index, added 2.28%.
Prior to today's trading, shares of the medical device maker had lost 4.68% over the past month. This has lagged the Medical sector's loss of 1.17% and was narrower than the S&P 500's loss of 5.73% in that time.
Market participants will be closely following the financial results of Hologic in its upcoming release. In that report, analysts expect Hologic to post earnings of $1.02 per share. This would mark a year-over-year decline of 0.97%. Meanwhile, the latest consensus estimate predicts the revenue to be $1 billion, indicating a 1.56% decrease compared to the same quarter of the previous year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $4.28 per share and a revenue of $4.08 billion, signifying shifts of +4.9% and +1.29%, respectively, from the last year.
It is also important to note the recent changes to analyst estimates for Hologic. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.08% lower within the past month. Hologic is currently sporting a Zacks Rank of #3 (Hold).
With respect to valuation, Hologic is currently being traded at a Forward P/E ratio of 14.38. This expresses a discount compared to the average Forward P/E of 28.15 of its industry.
It is also worth noting that HOLX currently has a PEG ratio of 2.04. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. Medical - Instruments stocks are, on average, holding a PEG ratio of 2.45 based on yesterday's closing prices.
The Medical - Instruments industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 78, positioning it in the top 32% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Hologic (HOLX) Advances But Underperforms Market: Key Facts
Hologic (HOLX - Free Report) closed the latest trading day at $61.89, indicating a +0.68% change from the previous session's end. The stock's change was less than the S&P 500's daily gain of 1.77%. Meanwhile, the Dow gained 1.42%, and the Nasdaq, a tech-heavy index, added 2.28%.
Prior to today's trading, shares of the medical device maker had lost 4.68% over the past month. This has lagged the Medical sector's loss of 1.17% and was narrower than the S&P 500's loss of 5.73% in that time.
Market participants will be closely following the financial results of Hologic in its upcoming release. In that report, analysts expect Hologic to post earnings of $1.02 per share. This would mark a year-over-year decline of 0.97%. Meanwhile, the latest consensus estimate predicts the revenue to be $1 billion, indicating a 1.56% decrease compared to the same quarter of the previous year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $4.28 per share and a revenue of $4.08 billion, signifying shifts of +4.9% and +1.29%, respectively, from the last year.
It is also important to note the recent changes to analyst estimates for Hologic. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.08% lower within the past month. Hologic is currently sporting a Zacks Rank of #3 (Hold).
With respect to valuation, Hologic is currently being traded at a Forward P/E ratio of 14.38. This expresses a discount compared to the average Forward P/E of 28.15 of its industry.
It is also worth noting that HOLX currently has a PEG ratio of 2.04. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. Medical - Instruments stocks are, on average, holding a PEG ratio of 2.45 based on yesterday's closing prices.
The Medical - Instruments industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 78, positioning it in the top 32% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.